J&J to Present New Data Highlighting Acuvue Oasys Max 1-Day for Astigmatism at AAOpt 2025

Johnson & Johnson Vision is set to present new clinical findings at the American Academy of Optometry’s annual meeting in Boston, showcasing the performance of its Acuvue Oasys Max 1-Day for Astigmatism contact lenses. According to data from a head-to-head patient study led by Giovanna Olivares and colleagues, the lenses outperformed Dailies Total1 for Astigmatism across multiple comfort and visual performance metrics.

Key findings from the study include:

       • 62% of participants preferred Acuvue Oasys Max 1-Day for overall vision, compared to 18% who favored Dailies Total1.

       • During digital device use, 65% selected Acuvue Oasys Max 1-Day, while only 16% preferred the comparator lens.

       • The lens scored consistently higher across end-of-day comfort, overall opinion, and visual satisfaction.

Johnson & Johnson attributes this performance to its proprietary TearStable™ Technology, OptiBlue™ Light Filter, and Blink Stabilized Design, which supports consistent lens alignment through natural blinking, regardless of head position or gaze direction.

A secondary study by Olivares, “Evaluation of Treatment Effects in a Study Comparing Two Daily Disposable Toric Soft Contact Lenses,” reinforced these results. Participants chose Acuvue Oasys Max 1-Day 3.3 times more often than Dailies Total1. Notably, when Acuvue was worn second in the trial sequence, positive feedback rose to 80%, compared to 33% for Dailies Total1, demonstrating a measurable order effect in favor of Acuvue’s performance.

Introducing the Acuvue Oasys Max 1-Day Multifocal for Astigmatism

In addition to its toric lens data, Johnson & Johnson will present findings from a study led by Eugene Appenteng Osae, evaluating the Acuvue Oasys Max 1-Day Multifocal for Astigmatism, the first and only daily disposable multifocal contact lens developed specifically for patients with both presbyopia and astigmatism.

The research showed that patients with 1.00 D to 1.75 D of refractive astigmatism experienced visual quality comparable to the non-toric multifocal version, offering a new, effective option for a previously underserved group of patients.

The multifocal toric lens is now commercially available in the US, Canada, and selected EMEA and APAC markets.